Early test: can a cancer drug shrink tumors before surgery?
NCT ID NCT01804712
Summary
This small, early-stage study tested whether giving the drug rituximab before prostate removal surgery could reduce the number of specific immune cells (B-cells) inside prostate tumors. Eight men with high-risk prostate cancer received four weekly doses of rituximab before their scheduled surgery. The main goal was to see if the drug changed the tumor's environment by measuring B-cell levels in tissue samples taken before and after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moores UCSD Cancer Center
La Jolla, California, 92093-0698, United States
Conditions
Explore the condition pages connected to this study.